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Propranolol blood levels and the effect of these levels on hemodynamic parameters were
evaluated in 25 patients with coronary artery disease undergoing cardiac catheterization and
coronary angiography. Fifteen patients were receiving high doses of propranolol (320-1920
mg/day) while ten patients were receiving conventional doses (80-240 mg/day). The high dose
propranolol group had significantly higher plasma propranolol levels than the conventional
dose group (788 ± 134 SD vs. 43 * 7.2 ng/ml SD), and there was a direct linear relationship
between propranolol dose and plasma drug levels (r = 0.85, P<0.001). There were no significant
differences between high and conventional dose propranolol groups in terms of all hemody-
namic parameters measured, namely ejection fraction, ventricular volume, cardiac index, or
peripheral vascular resistance. Despite high drug dosage and blood levels, only mild side effects
were seen.
INTRODUCTION
Although the use of propranolol generally is accepted for the treatment ofangina
pectoris, recommendations concerning the most approrpiate drug dosage still vary
[1,2,3]. On the one hand, it has been stated that drug dose be increased sequentially to
tolerance,-defined by bradycardia, hypotension, or fatigue; or to maximum relief of
anginal symptoms [1]. Alternatively, it has been suggested that maximum therapeutic
benefit occurs at relatively low doses of 160-240 mg per day and that higherdoses are
associated with clinical and hemodynamic deterioration [3,4]. Differences in patterns
ofpropranolol administration appear to be due to two factors: (1) variable therapeu-
tic responses observed over a wide range of drug doses [1,2,3] and (2) a lingering
suspicion that propranolol administration may result in deterioration ofleft ventricu-
lar performance [4,5,6].
A number of mechanisms could account for the observed individual variability of
propranolol doses required for an adequate therapeutic response. These include:
(1) differences in bioavailability and drug absorption resulting in suboptimal blood
173
This work was supported by a Yale University Institutional Research Grant and by the Medical
Research Service of the Veterans Administration Medical Center. Presented in part at the 51st National
Scientific Session, The American Heart Association, Dallas, Texas, 1978.
Address reprint requests to: Ruben A. Zito, M.D., Division of Cardiology, West Haven VA Medical
Center, West Haven, CT 06516
Copyright © 1980 by the Yale Journal of Biology and Medicine, Inc.
All rights of reproduction in any form reserved.and tissue drug levels [7,8]; (2) differences in drug levels necessary to attain adequate
beta blockade in individual patients, resulting from different levels of sympathetic
tone or differences in the actual number of beta receptors among patients [9,10];
(3) differences in regional myocardial drug availability resulting from reductions
in regional myocardial blood flow due to coronary occlusion or obstruction [11].
The issue ofwhether propranolol impairs ventricular function in a major negative
manner continues to be debated. Previous studies ofthe effects ofpropranolol on left
ventricular function have not shown uniform results [4,5,12,13,14]. Many of these
investigations reported a negative inotropic effect and development of regional wall
motion abnormalities following acute administration of intravenous propranolol
[4,5]. However, recent studies by Marshall et al. [15] and Reduto et al. [16] have not
demonstrated substantial alteration of ventricular performance by propranolol.
Using radionuclide techniques, they found no change in resting ejection fraction
induced by chronic oral doses of the drug. Furthermore, the epidemiologic study of
propranolol usage conducted by the Boston Collaborative Drug Surveillance Pro-
gram indicated that drug-induced heart failure is a relatively uncommon clinical
phenomenon [17]. In addition, adverse reactions do not appear to be dose-
dependent, frequently occurring at rather low doses.
The current trend ofantianginal therapy in our institution involves administration
of propranolol sequentially until either improvement of angina or development of
limiting symptoms or signs, irrespective of total dose. Because of this therapeutic
policy, we were able to evaluate a group of patients receiving a wide range of
propranolol dosages. This report describes initial studies in patients receiving both
high dose and more conventional doses of propranolol. The goals of the study were
twofold: (1) to assess ifvariation in dosage was a function ofdifferences inabsorption
or bioavailability and (2) to assess indirectly the hemodynamic consequences ofhigh
dose oral propranolol in patients with coronary artery disease.
MATERIALS AND METHODS
Patient Population
The study population consisted of 25 consecutive patients admitted to the West
Haven VA Medical Center for evaluation and treatment of incapacitating angina
pectoris. The mean patient age was 54 years with a range from 42 to 64 years. All
patients were eitherreceiving propranolol prior to hospital admission or had the drug
instituted subsequent to hospitalization. In each patient, the dose ofpropranolol was
increased until maximum tolerance, defined by heart rate less than 50 beats per
minute orimprovement ofsymptoms irrespective ofthe dose. Inaddition, all patients
received nitrates in the form of either sublingual isosorbide dinitrates, nitroglycerin
paste, or sublingual nitroglycerin. During the course of hospitalization, physical
activity was limited and patients were frequently kept at bed rest.
The patient population was divided arbitrarily into two groups based upon the
propranolol dosage: (1) those receiving propranolol doses > 320 mg per day,
constituting the high dose group (n = 15), (2) those receiving < 320 mg per day,
constituting the conventional dose (n = 10).
Fourteen patients had evidence of previous myocardial infarction (eight transmu-
ral and six nontransmural). No patient had sustained a myocardial infarction within
the month preceding the study. The diagnosis ofcoronary artery disease was obvious
clinically in all patients. Coronary angiography was performed in each patient. No
patient required intraaortic balloon placement as an adjunct to either therapy or
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angiography. Propranolol was administered for treatment ofangina (17 patients had
Class III angina; eight patients had Class IV angina). Nine patients had a history of
congestive heart failure and were being treated with digitalis and/or diuretics (five
patients in the high dose group and four in the conventional dose group), although all
were compensated clinically at the time ofstudy. On physicalexamination, no patient
manifested a third heart sound or significant pulmonary rales. Two patients had mild
liver abnormalities characterized by mild elevation of liver enzyme. None of the
patients had renal dysfunction.
Cardiac Catheterization and Angiography
Right and left cardiac catheterization was carried out by standard techniques.
Intracardiac pressure measurements, cardiac output determinations by the thermodi-
lution method, left ventricular cineangiography, and coronarycineangiography were
obtained in each individual. Single plane end-diastolic volume, end-systolic volume,
and ejection fraction were determined by the method of Dodge et al. [18].
Plasma Propranolol Levels
Blood samples for propranolol plasma levels were obtained six hours after
administration of the drug on the day of cardiac catheterization. Serum was frozen
and maintained at 0°C until assayed using the spectrophotofluorometric method of
Rao et al. [19]. This technique uses samples of 1 ml and has good reproducibility.
Data on serum propranolol measured by this technique correlate closely with
measurements obtained in the same sample by the method ofShand et al. [20] (n = 25
samples, r = 0.98) (Zito R: unpublished data).
Statistical Analysis
Data are expressed as the mean ± SD. The correlation coefficients between dose
and plasma levels were calculated from linear regression analysis. The differences
between the means were calculated using an unpaired t test.
RESULTS
Mean plasma levels ± SD of propranolol in the group of patients receiving high
dose of propranolol was 788 ± 134 ng/ml (range 132-920) and for the group on
conventional doses was 43 ± 7.2 ng/ml (range 10-85). A highly significant difference
(P< 0.001) existed between the mean plasma level ofpropranolol in the two groups.
Furthermore, a direct linear relationship (r = 0.85) was demonstrated between dose
administered and propranolol plasma levels (Fig. 1). Specifically, high doses of
propranolol were associated with high plasma levels. Despite the high doses utilized
and the high blood levels attained, only mild side effects were seen (mostly fatigue)
with the exception ofone patient who developed clinicalevidence ofcerebral vascular
insufficiency which improved when the dose was reduced. Congestive heart failure
was not detected in any patient. Seven ofthe 15 patients obtained symptomatic relief
oftheir angina when high doses ofpropranolol were utilized as compared to therapy
at low dose range.
The clinical characteristics of the patient population classified with respect to
propranolol dosage are shown in Table 1. No significant difference was found
between high and conventional dosage groups for age, sex, degree ofangina, history
of myocardial infarction, and extent of coronary artery disease. The hemodynamic
data for the two groups are shown in Table 2. Again, no significant differences were
175ZITO ET AL.
DOSE/PLASMA CONCENTRATION RELATIONSHIPS
X HIGH DOSE PROPRANOLOL
* CONVENTIONAL DOSE
N a 25
RS 0.85
PI 0.001
x
x
x
x
x
0 200 400 600 800 1000 1200 1400 1600 1800 2000
DOSE mg/DAY
FIG. 1. Relationship of oral propranolol dose in mg/day to plasma concentration in 25 patients. The
circles (o) represent the patients on conventional doses and the exes (x) the patients on high dose
propranolol.
found for heart rate, cardiac index, left ventricular end-diastolic pressure, peripheral
vascular resistance, end-diastolic volume, end-systolic volume, or ejection fraction.
DISCUSSION
The study indicates that high doses of oral propranolol are associated with
concomitant elevation of plasma drug levels. These high plasma concentrations of
TABLE I
ClinicalCharacteristicsofPatientGroups
HighDose ConventionalDose
(N= 15) (N= 10)
(> 320mg/day) (< 320mg/day)
Mean Range Mean Range P
Age 54yrs (42-64) 53yrs (43-64)
Sex 14male I female 10male
Angina
Classlll 10/15 7/10 NS
ClassIV 5/15 3/10 NS
PreviousMl 8/15 6/10 NS
ExtentofCAD
NumberofVessels 2.6 2.4 NS
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TABLE 2
Hemodynamic Measurements
High Dose Conventional Dose
(N= 15) (N= 10)
Mean ± SD (Range) Mean t SD (Range) P Normal Values*
Heart rate
beats/min 58 * 3 (52-66) 58±*6 (51-64) NS 60-100
Cardiac index
L/Min/M2 2.48 *0.43 (1.47-3.19) 2.33 * 0.51 (1.3-2.95) NS 2.5-3.6
Left ventricular
end-diastolic
pressure mmHg 15 * 7.0 (4-28) 13 * 5 (6-20) NS 2-12
Peripheral vascular
resistance
Dynes Sec CM-5 1487 * 355 (909-2015) 1303 * 206 (953-1542) NS 770-1500
Ejection fraction
(%) 59 * 12 (43-86) 60 * 8 (33-85) NS 55-78
End-diastolic
volume (ml) 126 * 47 (73-214) 122 * 47 (76-195) NS 70-104
End-systolic
volume (ml) 50 * 23 (27-99) 54 * 37 (19-95) NS 24-36
* Reference [25]
propranolol may be necessary to obtain appropriate antianginal responses in
individual patients. Although high doses are employed frequently for the treatment
of hypertension, little data is available concerning the effect of these dose ranges in
patients with coronary artery disease and a greater tendency to intrinsic left
ventricular dysfunction. In this selected group of patients, important therapeutic
effects appeared to occur without associated major side effects. No congestive heart
failure or further hemodynamic deterioration was precipitated by the doses of
propranolol employed in the high dose group. In addition, hemodynamic parameters
in patients treated with high doses of propranolol were not significantly different
from those seen in patients treated with conventional doses.
Work with antiarrhythmic agents such as quinidine and procainamide has estab-
lished distinct relationships between drug dose, drug blood levels, therapeutic
effectiveness, and toxicity. No such simple set of relationships exist for propranolol.
Many previous investigations have noted a wide variation in the drug dose necessary
for the treatment of both angina and hypertension [1,2,3,7,8]. Physiologic studies
likewise have demonstrated wide variations in the propranolol blood concentration
necessary to induce appropriate responses to isoproterenol infusion or exercise
[9,21]. As opposed to other drugs evaluated, there does not appear to be a clearly
defined therapeutic and toxic range of blood levels for propranolol. This should not
be too surprising, since the physiologic effects ofpropranolol are dependent upon the
interaction of the drug with the endogenous beta receptor population in the
individual patient. The number of cardiac receptors and the level of intrinsic beta
adrenergic activity on both a regional and systemic basis will have wide individual
variability. George et al. [10] have shown in dogs that there is a direct relationship
between propranolol and isoproterenol sensitivity. Animals more sensitive to intrave-
nous propranolol are far more sensitive to isoproterenol infusion, implying a
common receptor response. Recently an increase in the number ofreceptors has been
demonstrated in animals and humans chronically treated with propranolol [22,23].
These could explain the need of high dose of propranolol in some patients.
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Propranolol is metabolized primarily by the liver. Paterson et al. [8] have
demonstrated an active metabolite of propranolol (4 hydroxypropranolol) in the
serum after oral propranolol administration. This metabolite was not measured in
our study. However, this metabolite does not appear to be present after chronic oral
therapy and would therefore not influence the results ofour study [24]. Nevertheless,
it is possible that other, as yet not measured or defined, metabolite, may play a role in
the hemodynamic consequences of propranolol therapy.
Despite the high dosage utilized in many ofourpatients, only mild side effects were
seen. Only one patient of the high dose group developed a major complication, that
of cerebral vascular insufficiency. This improved when the dose was reduced.
Congestive heart failure was not detected in any patient. The latter results are in
agreement with those of the Boston Collaborative Surveillance Program [17].
However, it must be noted that the majority of patients in our study had severe
angina and were consequently symptom-limited and hospitalized. It is conceivable
that at higher levels of physical activity, evidence of altered cardiac reserve might
develop.
The present study employed doses as high as 1920 mg per day. Even at these high
doses there was no evident demonstration ofmajor abnormalities in cardiac function
different from those seen in comparable patients on conventional doses. Clearly, it
would have been optimal also to study patients during exercise stress at the onset of
therapy and then again as the dosage was increased. However, this option was not
available because of the symptomatic status of the patients studied and the fact that
hemodynamic measurements were made on only one occasion, at rest at the time of
cardiac catheterization and angiography. Nevertheless, our data support recent
preoperative observations made by Marshallet al. [15] and Reduto et al. [16], both of
whom failed to demonstrate any major deterioration in left ventricular function
induced by propranolol in patients with coronary artery disease studied sequentially.
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